Research has found that HSPB1 is closely related to the therapeutic effect of sorafenib [67, 68], and sorafenib, as the first‐line medication for HCC in clinical practice, is often considered the first choice for patients [68]. Here, HSPB1 is linked to hepatocellular carcinoma.